<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199078</url>
  </required_header>
  <id_info>
    <org_study_id>PALOMA II</org_study_id>
    <nct_id>NCT04199078</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.</brief_title>
  <acronym>PALOMA 2</acronym>
  <official_title>Ensayo clínico Aleatorizado, Abierto, Paralelo, Controlado, multicéntrico, Para Explorar la Eficacia Del Gel Vaginal Papilocare® en la reparación de la Mucosa Cervical Con Lesiones Causadas Por Virus Papiloma Humano de Alto Riesgo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procare Health Iberia S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adknoma Health Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Procare Health Iberia S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to
      evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal
      mucosa with lesions caused by HPV-HR. All the patients included in the study will be
      randomized (1:1:1:1) to Arm A (Papilocare schedule A), Arm B (Papilocare schedule B) and Arm
      C (Papilocare schedule C) Arm D (usual clinical practice-without treatment-).

      Selection period of 1 month, followed by randomization and 6 months of treatment followed by
      a period of another 6 months without treatment. Patients will visit the site into a total of
      5 visits throughout the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the repairment of the cervico-vaginal mucosa with concordant colposcopic image</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the repairment of the cervico-vaginal mucosa in positive high risk HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image, 6 months after the start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the repairment of the cervico-vaginal mucosa with concordant colposcopic image</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Evaluate the repairment of the cervico-vaginal mucosa in positive high risk HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image at 3 and 12 months after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of reeptielization degree of the cervico-vaginal mucosa by a likert-type scale</measure>
    <time_frame>3,6 and 12 months</time_frame>
    <description>A likert-type scale will be used to evaluate the reeptielization degree of the cervico-vaginal mucosa at 3, 6 and 12 months after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of vaginal health status by vaginal health index score (Bachmann)</measure>
    <time_frame>3,6 and 12 months]</time_frame>
    <description>The vaginal health index score (Bachmann) will be used to evaluate vaginal health status at 3, 6 and 12 months from the start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the satisfaction of papilocare gel use by a likert-type scale</measure>
    <time_frame>3 and 6 months]</time_frame>
    <description>A likert-type scale will be used to evaluate the satisfaction of papilocare gel use by the patients at 3 and 6 months after the start of treat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with good therapeutic compliance</measure>
    <time_frame>3 and 6 months]</time_frame>
    <description>Percentage of patients with good adherence to the treatment will be used to evaluate the therapeutic compliance at 3 and 6 months after the start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Human Papilloma Virus</condition>
  <condition>Human Papilloma Virus Infection</condition>
  <condition>Cervix Lesion</condition>
  <arm_group>
    <arm_group_label>A - papilocare alternative days treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - papilocare semiintensive treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - papilocare intensive treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm D: usual clinical practice - no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Papilocare vaginal gel</intervention_name>
    <description>Papilocare is a gel vaginally administered by a singledose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution</description>
    <arm_group_label>A - papilocare alternative days treatment</arm_group_label>
    <arm_group_label>B - papilocare semiintensive treatment</arm_group_label>
    <arm_group_label>C - papilocare intensive treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Woman between the ages of 30 and 65 (both inclusive).

          2. Able to read and understand the Patient Information Sheet and the Informed Consent
             form.

          3. Acceptance in the participation of the essay and signature of the Informed Consent
             form.

          4. ASC-US or LSIL or AG-US cytological result with concordant colposcopic image made at
             the screening visit.

          5. High risk HPV positive by PCR performed at screening visit.

          6. Is capable, at the discretion of the researcher, to comply with the requirements of
             the trial and without hindrance to follow the instructions and assessments throughout
             it.

        Exclusion Criteria:

          1. Clinically relevant immune system alterations, or any other autoimmune disease or in
             treatment with immunosuppressants.

          2. Non-diagnosed abnormal genital hemorrhage (during the 6 months prior to the screening
             visit).

          3. To had been vaccinated against HPV.

          4. Other symptomatic vulvovaginal infections.

          5. Surgical cervical excision in the last year or total hysterectomy.

          6. Previous history of gynecological cancer.

          7. Participation in any other clinical trial at present or in the 4 weeks prior to the
             inclusion of the trial.

          8. Any planned surgery that prevents the correct compliance with the guidelines.

          9. Use of vaginal contraceptives or other vaginal hormonal treatments.

         10. Contraindications for the use of Papilocare® gel or known allergies to any of its
             components.

         11. Women of childbearing age who do not use effective contraceptive methods, pregnant
             women, with suspicion of pregnancy or woman who are breastfeeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Cortes Bordoy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AEPCC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josep Combalia, MD</last_name>
    <phone>+34 936455441</phone>
    <email>combalia.j@procarehelath.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Complejo Hospitalario Torrecárdenas</name>
      <address>
        <city>Almeria</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Fiol, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Mancebo, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Josep Maria Solé, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igancio Lobo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assir Hospitalet de Llobregat</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08904</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Riera, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Manacor</name>
      <address>
        <city>Manacor</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Agüera, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Rodríguez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Gurrea, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlando Valenzuela, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The PIs from the participant sites gonna received the study protocol and the informed consent form previously to the initiation of the study and every time it occurs an amendment over the protocol, ICF or any other study document. Once the study has finished and the data has been analyzed, the PI's from the sites gonna received the CSR.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

